Interested in learning how Immunophotonics, Inc. continues to explore the ability of IP-001 to transform a routine interventional-oncology procedure into...

Immunophotonics has strengthened its leadership with the appointment of Miguel Zubizarreta to its Board of Directors. Mr. Zubizarreta, a tech...

Look for Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. in New Orleans at the American Association for...

Immunophotonics continues to attract investments that will fund research and clinical trials regarding the use of the company’s lead drug...

Lu Alleruzzo, CEO; Tomas Hode, CIO & President; and the Immunophotonics Team want to congratulate Dr. Wei Chen on being...

Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. attended the SIO 2022 annual scientific meeting March 24 –...

Lu Alleruzzo co-founder and CEO of Immunophotonics attended the NYSE 9th Annual 2022 IPO Summit. Very inspiring to hear from...

The continued success of Immunophotonics is driven by the dedication and hard work of our team. Immunophotonics was one of...

Immunophotonics, Inc. was recently awarded a Small Business Innovative Research (SBIR) Phase I and Phase II Fast-Track grant for research...

Hot off the press: Another part of the mechanism of action of how IP-001 (GC) remodels the tumor microenvironment revealed!...